



# Molecular Diagnostics for Bacterial Meningitis

**Xin Wang**

Chief, Bacterial Meningitis Laboratory  
Director, WHO Collaborating Center for Meningitis  
MVPDB/DBD/NCIRD/CDC

*Virtual Course on Bacterial Meningitis: Diagnosis, Surveillance, and Treatment, PAHO August 5-27<sup>th</sup>*

# Outline

---

**IMPORTANCE OF  
RAPID DIAGNOSTIC  
TESTS FOR BACTERIAL  
MENINGITIS**

**CURRENT LAB  
DIAGNOSTICS**

**LAB DEVELOPED rt-  
PCR TESTS**

**FUTURE MOLECULAR  
DIAGNOSTICS**

**CULTURE FOR OTHER  
SURVEILLANCE  
PROGRAMS**


# Importance of Rapid Diagnostics for Bacterial Meningitis

- Bacterial Meningitis is a life-threatening disease
- Rapid detection of meningitis pathogens is critical for case management, surveillance, and outbreak investigations
- Limitations of existing diagnostic tests prevent their wide usage
  - Culture: low recovery rate due to antibiotic use prior to specimen collection, improper storage/transport conditions etc.
  - Subcellular detection methods: polysaccharide antigen or nucleic acid-based
- Needs for development of next generation rapid tests

# Current Lab Diagnostics for Bacterial Meningitis

# Latex agglutination tests


- Target various meningitis pathogens but not all meningococcal serogroups
- Rapid (< 20 mins)
- High cost
- Cold chain for storage/distribution
- Performance may vary
  - lab verification: 33-100% sensitivity; 93-100% specificity
  - field evaluation: 69-80% sensitivity; 81-94% specificity




# Immuno-chromatographic tests

- Sp and all meningococcal serogroups except B
- Rapid (<15 mins)
- Cassette format expensive
- Cold chain for storage/distribution
- High sensitivity and specificity

Duplex Dipstick



MeningoSpeed



## Latex agglutination tests



Kit	Target pathogens	Specimen Type	Time	No. of Tests per Kit	Cost per Kit	Limitations
<b>Wellcogen™ Bacterial Antigen Kit</b>	group B <i>Streptococcus</i> , <i>H. influenzae</i> serotype b, <i>S. pneumoniae</i> , <i>N. meningitidis</i> serogroups A, C, Y or W, <i>N. meningitidis</i> group B/ <i>E. coli</i> K1	Blood culture Plate culture± CSF, Serum urine	3 mins	30	\$1967+	<ul style="list-style-type: none"> <li>• Not all meningitis pathogens are covered</li> <li>• Cold chain required</li> <li>• Operation by trained/experienced staff</li> <li>• Cross-reactivity with other bacterial species</li> </ul>
<b>Pastorex™ Meningitis</b>	<i>N. meningitidis</i> groups A, C, Y or W, <i>E. coli</i> K1, <i>H. influenzae</i> serotype b, <i>S. pneumoniae</i> , group B <i>Streptococcus</i>	Blood culture CSF, Serum urine	5 to 10 mins	25	\$384 <sup>‡</sup>	
<b>BD Directigen™ Meningitis Latex Test System</b>	<i>H. influenzae</i> serotype b, <i>S. pneumoniae</i> , <i>N. meningitidis</i> groups A, B, C, Y or W, <i>E. coli</i> K1, group B <i>Streptococcus</i>	Blood culture CSF*, serum* urine	15 to 20 mins	90	\$2464+	
<b>Phadebact™ CSF Test (require -80°C incubator)</b>	<i>S. pneumoniae</i> , <i>H. influenzae</i> serotype b, <i>N. meningitidis</i> serogroup A, B, C, Y, W and <i>S. agalactiae</i>	CSF, Serum Urine	10-15 mins	20	1242	

## Immunochromatographic tests

Test	Target	Specimen Type	Time	No. of Tests per Kit	Cost per kit	Limitations
<b>CERMES Duplex Dipstick</b>	<i>N. meningitidis</i> serogroup A, C, Y, and W	CSF	10 to 15 mins	N/A	N/A	<ul style="list-style-type: none"> <li>• Not all Nm serogroups are detected</li> <li>• Sp serotypes are not detected</li> <li>• Not all meningitis etiological agents are detected</li> <li>• Large specimen volume required for test</li> </ul>
<b>NmX dipstick</b>	<i>N. meningitidis</i> serogroup X	CSF, Bacterial suspension in PBS	10 to 15 mins	N/A	N/A	
<b>BioSpeedia MeningoSpeed</b>	<i>N. meningitidis</i> serogroups A, C, Y, W, and X	CSF	3 to 10 mins	20	\$545	
<b>BioSpeedia PneumoSpeed</b>	<i>S. pneumoniae</i>	CSF, urine	3 to 15 mins	20	\$136	
<b>Abbott™ BinaxNow® AgCard</b>	<i>S. pneumoniae</i>	CSF, urine	15 mins	22	\$374	

# PCR-based tests

- Relatively fast (1-5 hrs)
- Sensitive/specific for pathogen detection
- High throughput and rapid data reporting
- Multiple platforms available
- Certain tests implemented in a number of African countries



- High cost
- Decentralization to regional/district levels may be challenging
- Require technical trainings and lab infrastructure (freezer, fridge, separate rooms etc)
- Requires effective transport systems for specimen referral





# Examples of PCR-based tests

Test	Platform	Targets	Specimen Type	Availability	Instrument	Time
<b>M-DiaSero (Belgium)</b>	Traditional rt-PCR, monoplex	<i>Neisseria meningitidis</i> (Serogroups A, B, C, W and Y)	Blood, CSF, Swab	EU/S. Africa	ABI, Bio-Rad, Qiagen, LC480	Up to 4 hrs
<b>HG Meningococcus (Ireland)</b>	LAMP	<i>Neisseria meningitidis</i> (Serogroups A, B, C, E, W, X, Y, and Z)	Blood, CSF, Swab, Direct CSF	EU	LAMP instrument	<60 mins
<b>Real-time PCR Detection Kit for Neisseria Meningitidis (China)</b>	Traditional rt-PCR, multiplex	<i>Neisseria meningitidis</i> (Serogroups A, B, C, E, W, X, Y, and Z)	CSF	China	N/A	N/A
<b>CDC rt-PCR</b>	Direct PCR, triplex	<i>Neisseria meningitidis</i> (Serogroups A, B, C X, W, and Y)	CSF, serum		ABI, AriaMx	2 hrs

**Laboratory Developed Real-Time PCR Tests (CDC)**

# rt-PCR for the detection of meningitis pathogens and capsular genotypes


- High sensitivity/specificity (>95%)
- Implemented in a number of countries
- Procurement of key reagents through IRR, an online ordering system that supports 45 countries
- EQA program in place to ensure data quality
  - WHO PT/CDC Retesting



## Specimen types:

- CSF for direct rt-PCR
- CSF, blood and other body fluids for traditional rt-PCR

# Species-specific real-time PCR tests




Target Pathogen	Gene function	Gene/amplicon size (bp)	Strain covered
<i>Neisseria meningitidis</i>	<i>sodC</i> -Superoxide dismutase	560/127	Groupable and non-groupable
<i>Haemophilus influenzae</i>	<i>hpd</i> -Haemophilus protein D	1095/151	Typable and non-typable
	<i>phoB</i> -DNA binding response regulator*	696/106	Typable and non-typable ( <i>hpd</i> -)
<i>Streptococcus pneumoniae</i>	<i>lytA</i> -autolysin	957/51	Typable and non-typable


\*also known as phosphate regulon transcriptional regulatory protein

[\(two component system DNA-binding response regulator \[Haemophilus influ - Protein - NCBI \(nih.gov\)\]\)](#)


# Capsule biosynthesis genes as targets for Nm serogrouping



# Hi capsule locus



# rt-PCR testing algorithm



# **Future Molecular Diagnostics for Bacterial Meningitis**



# Next generation rapid tests: a key objective for defeating meningitis by 2030

## Use case 3

- Affordable multiplex diagnostic test to identify pathogens
- Hospital settings
- Inform treatment plans

# Timelines for use case 3 development

2017: A call for action: global vision to defeat meningitis

2020: Use case 3 TPP finalized

2021: Identification of potential platforms for use case 3

**WE  
ARE  
HERE**

2018: Expert group meeting: discussed IVD tests development and use cases

2020-21: Use case 3 landscape and Market analysis by PATH

2022-24: Development and validation of potential RDTs

# Exploring multiplex molecular diagnostic tests

## Portable real-time PCR platforms



Platform	Features	Run Time	Power	Estimated Instrument Cost
<b>Q-POC (UK)</b>	Cassette Multiplex (up to 40 targets)	10-30 minutes	Battery powered	\$3000
Anitoa Maverick compact qPCR system (US)	4-8 wells Multiplex (up to 4 targets)	~30 minutes	10V, battery backup option	\$3500-6000
Coyote Mini8 Plus Real-Time PCR System (Germany)	8 wells Multiplex (up to 2 targets)	<2 hours	12V Battery pack	\$6000-\$8000
Bio molecular Systems Mic qPCR (Australia)	48 wells Multiplex (up to 4 targets)	~25 minutes	100-240V	\$15000
Q160 Mini Real-Time PCR System (China)	16 wells Multiplex (up to 2 targets)	1-2 hours or less	85-265V	\$4600
Handheld real-time PCR device (prototype)	4 wells	~35 minutes	?	?

- Highly sensitive and specific
- Affordable
- Small/compact device
- Battery powered
- Multi-pathogen detection
- Expandable-able to include serogroup/serotype specific targets or gene targets associated with AMR

# Other potential diagnostic platforms


---

- Metagenomic next generation sequencing
  - Growing interest in past 10 years
  - Used for detection of bacterial and viral pathogens
  - Various platforms (MinION, Illumin supported platforms, Ion Torrent, BGISEQ etc) and analysis tools available
  - Higher cost and lower sensitive compared to PCR-based tests
  - Targeted approaches offer better sensitivity, reduced cost, and decreased complexity of bioinformatic analysis



# Other potential diagnostic platforms

- CRISPR-based detection system
  - Rely on Cas protein, an endonuclease that cleave complementary sequences
  - Cleavage induces nonspecific cleavage of single stranded DNA or RNA, which can be modified with reporter/quencher, allowing signal detection
  - Applied to viral pathogen detection



# Culture for other surveillance programs

- Culture remains valuable for surveillance programs such as AMR and genomic surveillance
  - Bacterial isolates are still needed for antimicrobial susceptibility testing and whole sequencing with the existing technologies
- AMR surveillance
  - Monitor AMR trends and emerging AMR in healthcare settings
  - Inform AMR prevention and control strategies
- Genomic surveillance
  - Monitor hyperinvasive, epidemic-prone, or high transmissible strains
  - Trace meningococcal spread and transmission during outbreak setting



**Thank you for your attention**